COMPARISON OF COST EFFECTIVENESS OF MEDICAMENT IN ANTI-DIABETIC PATIENT
Wanjari B.E.*, Purohit A.D., Khalode K.D. and Bhandarkar K.R.
ABSTRACT
Diabetes is fast gaining the status of a potential epidemic in India, with >62 million individuals currently diagnosed with the disease. India currently faces an uncertain future in relation to the potential burden that diabetes may impose on the country. The diabetes mellitus type- II (T2DM) in India, many interventions can reduce the burden of this disease. A prospective cross-sectional study was performed to assess the cost-effectiveness of antidiabetic drugs in patients with T2DM. Face-to-face interviews were conducted by using a validated questionnaire in a total of 45(29 males, 16 females) patients with T2DM from GMC Hospital Gondia, RH Tirora, RH Goregaon. Cost-effectiveness was determined on the basis of cost of antidiabetic drug/s, efficacy, adverse drug reactions, safety of administration, frequency of administration, and bioavailability. The treatment of T2DM in participants, Glibenclamide And Metformin HCl costed least (Rs.3.3) per unit of effectiveness followed by Glimepiride (Rs.11.2), Gliclazide (Rs.10.8), Metformin(Rs.11.9), and Glipizide (Rs.5.7).
Keywords: Antidiabetic, Cost-effectiveness, Diabetes mellitus.
[Full Text Article]
[Download Certificate]